Development and characterization of an aptamer binding ligand of fractalkine using domain targeted SELEX.
Fractalkine (FKN) is a unique cell surface protein with potential as a therapeutic target because of its role in inflammatory diseases and cancer. We developed an aptamer, named FKN-S2, with a dissociation constant of 3.4 ± 0.7 nM that is specific to the chemokine domain of fractalkine.